| SCIENCE NEWS | Threshold Pharmaceuticals to Present Updated Data from Phase IIb Clinical Trial of TH-302 in Combination with Gemcitabine in Advanced Pancreatic Cancer Threshold Pharmaceuticals, Inc. announced that data from a randomized open-label phase IIb clinical trial of investigational hypoxia-targeted drug TH-302 in patients with advanced pancreatic cancer, will be presented. [Press release from Threshold Pharmaceuticals, Inc. discussing data to be presented at European Society for Medical Oncology 2012 Congress (ESMO), Vienna] Press Release |
|
|
|